



RETURN TO YOU

Keep recurrent *C. diff* infection from coming back with **REBYOTA**™

INDICATION

REBYOTA (fecal microbiota, live - jslm) is indicated for the prevention of recurrence of *Clostridioides difficile* (*C. diff*) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent *C. diff* infection.

Limitation of Use

REBYOTA is not indicated for the treatment of *C. diff* infection.

IMPORTANT SAFETY INFORMATION

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.



Scan to visit
REBYOTA.com

Please see Important Safety
Information throughout and on page 10.
Click to see full [Prescribing Information](#)



C. DIFF INFECTIONS CAN COME BACK

C. diff can be a gut-wrenching experience. Even after antibiotic treatment, for some people, it can come back more than once.



Up to 35% of people who get a *C. diff* infection may have a recurrence^{1,2}



Up to 65% of people who experience a recurrence may have a second or third or more^{3,4}

What could happen if a *C. diff* infection comes back...

- Continued pain and diarrhea⁵
- Extended stays in the hospital⁶
- A life-threatening medical emergency called sepsis⁷
- Surgery to remove parts of your colon (colectomy)⁷
- For some people, it can even be fatal¹



ABOUT REBYOTA™

REBYOTA is the first and only single-dose, FDA approved microbiome-based treatment to keep recurrent *C. diff* infection from coming back, after you've already taken antibiotics⁸

- REBYOTA is not an antibiotic. It is a microbiota-based treatment that's delivered where it's needed, the gut microbiome
- REBYOTA is delivered at your doctor's office, and is administered within minutes. No laxatives/bowel prep or fasting required

This is Melissa's story



Scan to
watch or visit
REBYOTA.com

“ Had this treatment been available sooner, I would have asked for it....The healing process began after I had it. ”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

Click to see full [Prescribing Information](#)
Melissa was compensated for her time.
Individual results may vary. Talk to your doctor.



Melissa, Clinical Study Patient

IMPORTANT SAFETY INFORMATION (Continued)

You should report to your doctor any infection you think you may have acquired after administration.

Please see Important Safety Information throughout and on page 10.
Click to see full [Prescribing Information](#)



REBYOTA™ EFFICACY AND SAFETY PROFILE

In a major clinical study with REBYOTA^{8,a}

REBYOTA +
Antibiotics

71%

success rate^{8,b}

Antibiotics
Alone

58%

success rate^{8,b}

Of those patients who saw success with REBYOTA...

~90% Stayed Free of *C. diff* at 6 Months⁹

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).⁸

In clinical studies, there were no serious adverse events related to REBYOTA.⁸

^aThe study was conducted in approximately 300 adult patients with recurrent *C. diff* infection for up to 8 weeks to find out how well REBYOTA prevented recurrent *C. diff* infection. Patients in this study first completed treatment with antibiotics.⁹

^bSuccess rate indicates no other recurrence of *C. diff* infection at 8 weeks.

IMPORTANT SAFETY INFORMATION (Continued)

REBYOTA has not been studied in patients below 18 years of age.

Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

Please see Important Safety Information throughout and on page 10. Click to see full [Prescribing Information](#)


REBYOTA™
(fecal microbiota, live-jslm) suspension
for rectal use

TREATMENT WITH REBYOTA™



- REBYOTA is administered in your doctor's office within minutes⁸
- REBYOTA is delivered rectally to your gut microbiome, where it's needed
- REBYOTA requires no laxatives/bowel prep, fasting, anesthesia, or colonoscopy

This is Freda's story



Scan to
watch or visit
REBYOTA.com

“I just knew that if I had *C. diff* again, I wasn't going to survive. But my *C. diff* didn't come back after I had my treatment.”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

Click to see full [Prescribing Information](#)

Freda was compensated for her time.

Individual results may vary. Talk to your doctor.



Freda, Clinical Study Patient

Please see Important Safety Information throughout and on page 10. Click to see full [Prescribing Information](#)




TREATMENT WITH REBYOTA™



BEFORE TREATMENT⁸

- You should complete your antibiotic prescription 1 to 3 days before your REBYOTA treatment
- No laxatives/bowel prep or fasting required



DURING TREATMENT⁸

- Anesthesia or colonoscopy are not necessary
- The doctor or nurse will place you in the preferred position for the administration
- Administration happens within minutes
- You will be asked to remain in place for about 15 minutes to minimize any cramping that may occur



AFTER TREATMENT⁸

- You can go home after treatment
- Follow your doctor's instruction

Talk to your doctor...

- If any side effects persist
- Before taking antibiotics for any reason for 8 weeks after treatment with REBYOTA

Most common side effects (see below) could occur during the first 2 weeks after treatment. This may not mean your recurrent *C. diff* has come back.

IMPORTANT SAFETY INFORMATION (Continued)

REBYOTA may contain food allergens.

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).

Please see Important Safety Information throughout and on page 10.
Click to see full [Prescribing Information](#)



FREQUENTLY ASKED QUESTIONS

What is **REBYOTA**TM?⁸

REBYOTA is a liquid mix of trillions of live microbes—including *Bacteroides*—sourced from the stool of qualified human donors. Each dose and donor have been tested and screened to help address product safety.

How do I receive **REBYOTA**?⁸

REBYOTA is a 150-mL liquid solution that is rectally administered to deliver live microbes where they are needed—your gut microbiome.

REBYOTA is given in just one dose, in one visit.

**TALK TO YOUR DOCTOR TO FIND OUT IF REBYOTA
IS RIGHT FOR YOU.**

This is Patricia's story



Scan to
watch or visit
REBYOTA.com

“For me, it was one dose and one visit, and that was it. I was able to hug and squeeze my girls again.”

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

[Click to see full Prescribing Information](#)

Patricia was compensated for her time.

Individual results may vary. Talk to your doctor.



Patricia, Clinical Study Patient

**Please see Important Safety
Information throughout and on page 10.
[Click to see full Prescribing Information](#)**


REBYOTATM
(fecal microbiota, live-jslm) suspension,
for rectal use

REBYOTA™ SUPPORT

YOU COULD PAY AS LITTLE AS \$100^a

Commercially insured, eligible patients can save on each prescription with the **REBYOTA Co-pay Program**.

- For commercially insured individuals whose insurance plans cover REBYOTA
 - Must be 18 years of age or older
 - Offer valid only in the US
 - Must have been administered REBYOTA for an FDA approved indication
-

To learn more about the **REBYOTA Co-pay Program** and to enroll, please speak with your doctor.

REBYOTA Patient Assistance Program^a

You may be eligible to receive **REBYOTA** at no cost if you qualify for the Ferring **REBYOTA Patient Assistance Program**.

Eligibility requirements:

Open to uninsured and underinsured patients who meet the following eligibility criteria:

- You must be prescribed REBYOTA for an FDA approved indication
 - You reside in the US
 - You are being treated by a US-licensed healthcare provider
 - Income restrictions apply
-

To learn more about the **REBYOTA Patient Assistance Program** and to see if you qualify, please speak with your doctor.

^aAvailable only for patients who meet eligibility requirements. Programs do not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/23.

Please see Important Safety Information throughout and on page 10. Click to see full [Prescribing Information](#)





My C. diff Conversation Guide

My Responses

Before you talk to your doctor, you can help ensure you receive the right treatment. Read this discussion guide. Being able to ask your doctor questions and share your thoughts can help you get the best care. Talk to your doctor if you are concerned about having C. diff or a recurrent C. diff infection.

Have you recently been diagnosed with C. diff or a recurrent C. diff infection?

Yes ☐ No ☐

Are you concerned that your C. diff infection has come back?

Yes ☐ No ☐

Are you experiencing the following symptoms? Check all that apply.

☐ Watery Stool ☐ Blood in Stool ☐ Abdominal Pain ☐ Loss of Appetite

Are you experiencing the following symptoms? Check all that apply.

☒ Watery Stool ☐ Blood in Stool ☐ Abdominal Pain ☐ Loss of Appetite

Additional information to help your doctor understand you better.

1. How long has this been going on?

2. How often are you having these symptoms?

3. What are you taking to help with these symptoms?

4. What are the side effects of REBYOTA?

5. What are the side effects of REBYOTA?


Please see full Important Safety Information and full Prescribing Information on page 10.

Ready to talk to your doctor about C. diff?

Prepare to ask the right questions to get the right treatment. **Create your custom doctor discussion guide** by answering a few questions about your condition.



Scan to build your guide or visit REBYOTA.com



C. diff Diary

Prepare for productive discussions with your doctor.

Record important information about your C. diff journey in this diary and bring it to your appointment. Please note: This diary is a tool to help you prepare for your appointment. It is not a substitute for your doctor's advice.

This diary is intended for use by patients with C. diff infection. It is not intended for use by patients with other types of diarrhea.

This C. diff diary is intended for use by patients 18 years of age and older.

Print Your C. diff Diary

This diary is a standard PDF format. You may print either a full-page version or a smaller, single-page version.

On a Mac, select the "File" button at the top left of your computer screen. Click down to the "Print" option. Select the "Print" option to print the diary. Select the "Print" option to print the diary.

On a PC, select the "Print" button in the menu. Select your printer and click the "Print" button.

Is it an emergency?

If you feel that you are in immediate danger or an emergency, call 911 or go to the nearest emergency room. Please note: This C. diff diary is not intended as a substitute for your doctor's advice or advice.


Notes

Track Your C. diff Journey

Prepare for your doctor appointments with this printable **C. diff diary**. Track medical history, symptoms, questions, food and water intake, and more.



Scan to print your diary or visit REBYOTA.com



C. diff Caregiver Checklist

Before you take care of someone with C. diff infection, read this checklist. It will help you understand what to expect and how to take care of someone with C. diff infection.

Keep yourself and your loved one safe

Follow these steps to help prevent the spread of C. diff infection:

- Hand hygiene: Wash hands with soap and water before and after eating and using the bathroom.
- Clothing and laundry: Use laundry that contains chlorine bleach to kill bacteria, and only use it for laundry.
- Controlled waste: If possible, people with C. diff infection should be isolated in a private room, with a bathroom only for that person.
- Protective gear: Disposable gloves or gowns may be required for visitors when near hospitalized patients with C. diff infection.

Advocacy Groups

Find out more about advocacy groups to connect with people who understand your situation.

Groups focused on C. diff

C. diff Foundation: www.cdifffoundation.org

People With C. diff: www.peoplewithcdiff.org

Groups focused on caregivers

Caregiver Action: www.caregiveraction.org

National Alliance for Caregivers: www.nacaregivers.org

Helpful resources for you and your loved one

Communication

Communication is key to getting the best care for you and your loved one. Here are some tips to help you communicate effectively:

- Be clear and concise.
- Listen to what the other person has to say.
- Ask questions if you don't understand.
- Take notes during the conversation.
- Bring a list of questions to the conversation.

Advocate for a Loved One

This **C. diff Caregiver Checklist** will help you take care of your loved ones with C. diff infection.



Scan to download your checklist or visit REBYOTA.com

Please see Important Safety Information throughout and on page 10. Click to see full [Prescribing Information](#)

IMPORTANT SAFETY INFORMATION

INDICATION

REBYOTA (fecal microbiota, live - jslm) is indicated for the prevention of recurrence of *Clostridioides difficile* (*C. diff*) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent *C. diff* infection.

Limitation of Use

REBYOTA is not indicated for the treatment of *C. diff* infection.

IMPORTANT SAFETY INFORMATION

- You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
- You should report to your doctor any infection you think you may have acquired after administration.
- REBYOTA may contain food allergens.
- Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
- REBYOTA has not been studied in patients below 18 years of age.
- Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Click to see full [Prescribing Information](#)



REFERENCES

1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med*. 2015;372(9):825-834.
2. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of *Clostridium difficile* infection: fidaxomicin versus vancomycin. *Clin Infect Dis*. 2012;55(suppl 2):S154-S161.
3. Kelly CP. Can we identify patients at high risk of recurrent *Clostridium difficile* infection? *Clin Microbiol Infect*. 2012;18(suppl 6):21-27.
4. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. *Clostridium difficile* infection. *Nat Rev Dis Primers*. 2016;2:16020.
5. Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in *Clostridium difficile* infection and nosocomial diarrhea. *J Clin Microbiol*. 2013;51(9):2884-2892.
6. Nelson WW, Scott TA, Boules M, et al. Health care resource utilization and costs of recurrent *Clostridioides difficile* infection in the elderly: a real-world claims analysis. *J Manag Care Spec Pharm*. 2021;27(7):828-838.
7. Feuerstadt P, Boules M, Stong L, et al. Clinical complications in patients with primary and recurrent *Clostridioides difficile* infection: a real-world data analysis. *SAGE Open Med*. 2021;9:2050312120986733.
8. REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
9. Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double blind, placebo controlled trial with a Bayesian primary analysis for the prevention of recurrent *Clostridioides difficile* infection. *Drugs*. 2022;82(15):1527-1538.

**Please see Important Safety
Information throughout and on page 10.
Click to see full [Prescribing Information](#)**





The content in this brochure is for informational purposes only and is not intended to replace a discussion with a healthcare professional.



**Scan to visit
REBYOTA.com**



Microbiome
Therapeutics
Development

Ferring and the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
REBYOTA is a trademark of Ferring B.V.
©2023 Ferring B.V. All rights reserved. US-REB-2200137-V3 6/23

